http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-097685-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2869 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001144 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2014-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-097685-A1 |
| titleOfInvention | METHODS OF USE OF ANTI-LGR5 ANTIBODIES |
| abstract | Methods of using anti-LGR5 antibodies are provided herein, for example, to treat a hedgehog-related disease that includes basal cell carcinoma. Claim 1: A method of treating a hedgehog-related disease in an individual comprising administering to the individual an effective amount of an anti-LGR5 antibody. Claim 18: The method according to any of claims 1-17, wherein the anti-LGR5 antibody has the formula Ab- (L-D) ₚ, wherein: (a) Ab is the anti-LGR5 antibody; (b) L is a linker; (c) D is a drug selected from a maitansinoid, an auristatin, a calicheamycin, a pyrrolobenzodiazepine and a nemorubicin derivative; and (d) p varies from 1-8. Claim 20: The method according to claim 18, wherein D has the formula (1) and wherein R² and R⁶ are each methyl, R³ and R⁴ are each isopropyl , R⁵ is H, R⁷ is sec-butyl, each R⁸ is independently selected from CH₃, O-CH₃, OH and H; R⁹ is H; and R¹⁸ is -C (R⁸) ₂-C (R⁸) ₂-aryl. Claim 22: The method according to claim 18, wherein D is a pyrrolobenzodiazepine of the formula (2) wherein the dotted lines indicate the optional presence of a double bond between C¹ and C² or C² and C³; R² is independently selected from H, OH, = O, = CH₂, CN, R, OR, = CH-RD, = C (RD) ₂, O-SO₂-R, and COR and optionally also selected halo or dihalo, where RD is independently selected from R, CO₂R, COR, CHO, CO₂H and halo; R⁶ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR, NO₂, Me₃Sn and halo; R⁷ is independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR, NO₂, Me₃Sn and halo; Q is independently selected from O, S and NH; R¹¹ is H or R or, when Q is O, SO₃M, where M is a metal cation; R and R are each independently selected from optionally substituted C₁₋₈ alkyl, C₃₋₈ heterocyclyl and C₅₋₂₀ aryl groups and optionally in relation to the NRR, R and R group together with the nitrogen atom to which they are joined form an optionally substituted heterocyclic ring of 4, 5, 6 or 7 members; R¹², R¹⁶, R¹⁹ and R¹⁷ are as defined for R², R⁶, R⁹ and R⁷, respectively; R is a C₃₋₁₂ alkylene group, the chain of which may be interrupted by one or more heteroatoms and / or aromatic rings that are optionally substituted; and X and X are independently selected from O, S and N (H). |
| priorityDate | 2013-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.